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1.1 Problem definition 
 
Human gut microbiota is composed of approximately 160 species per individual, and 
Bifidobacterium spp. is one of them (Rodríguez et al., 2015). Bifidobacteria confer 
benefits to the host including, but not limited to, the prevention of intestinal infection, 
the synthesis of pyridoxine (vitamin B6), and the enhancement of gut immunity (Shah, 
2002). Therefore, supporting their growth is desirable, both from the consumer point of 
view and the industrial point of view (for instance, functional ingredients manufacturers).  
One of the substances that benefit these commensal microorganisms is 
oligosaccharides. Oligosaccharides are found not only in fruits and vegetables but also 
in milk. Human milk oligosaccharides (HMOs) have been studied extensively in the 
recent decades in relation to their prebiotic effects (Bode, 2009; Coppa et al., 2004). 
However, human milk is not readily available in normal households. Instead, bovine 
milk is vastly produced all around the world including European countries (Eurostat, 
2017). Thus, it is much more readily available than human milk.  
Bovine milk contains oligosaccharides in free- and bound-form. One example of the 
latter is glycoproteins. They can present in the casein fraction, whey fraction, and milk 
fat globule membrane (MFGM) fraction of the milk (O’Riordan et al., 2014). Among 
the casein family (α-, β-, κ-, γ-casein), only κ-casein (κ-CN) can conjugate with 
carbohydrate. K-CN is composed of 169 amino acids, and the potential carbohydrate-
bearing portion is 64-amino acid from the carbon terminal. It is known as 
caseinomacropeptide (CMP) and can be found in the rennet whey during cheese-making. 
Approximately 40% of the rennet whey generated in the European dairy industry is used 
as livestock feed, as fertilizer, or simply discharged as waste (Macwan et al., 2016).  
CMP is worth an attention as it has been demonstrated to promote bifidobacterial 
growth (Azuma et al., 1984; Cicvárek et al., 2010). This growth-promoting activity was 
claimed to be attributed by both the polypeptide as well as the associated glycans. 
However, contradictory results were also found and the researchers argued that the 
growth-promoting effect was only because of the polypeptide itself (Poch & 
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Bezkorovainy, 1991; Robitaille, 2013). Since the data available to date is non-
conclusive, this project was aimed to gain insight of the potential beneficial effect of 
bovine CMP on the growth of bifidobacteria, emphasizing on the bifidobacterial ability 
to utilize the glycosylated chains.  
 
1.2 Research objectives 
 
To achieve the goal, the objectives of this project were, firstly, to study the utilization 
of bovine glycosylated CMP by Bifidobacterium longum subsp. infantis (B. infantis) 
ATCC 15697, Bifidobacterium bifidum (B. bifidum) ATCC 29521, and Bifidobacterium 
longum subsp. longum (B. longum) ATCC 15707; and secondly, to investigate the 
growth-promoting effect of CMP on these strains.  
Following that, two research questions were formulated. First, is glycosylated CMP 
utilizable by B. infantis ATCC 15697, B. bifidum ATCC 29521, and B. longum ATCC 
15707? And second, does CMP confer a growth-promoting effect on these strains?  
 
1.3 Hypotheses  
 
B. infantis, B. bifidum, and B. longum were selected since they are commonly added 
into dairy products such as yogurt and cheese (Lourens-Hattingh & Viljoen, 2001). 
Nevertheless, they differ from one another in terms of the availability of carbohydrate-
metabolizing enzymes, among all aspects. One major difference among these three 
strains is the production of sialidases. B. infantis possesses sialidase, B. bifidum produces 
a similar battery of enzymes like B. infantis except that it only liberates sialic acid 
residues but leaves them unutilized, whereas B. longum does not produce sialidases 
(Ward et al., 2007).  
Hence, it was hypothesized that meanwhile B. infantis can fully utilize the 
glycosylated CMP as the building blocks for its growth, B. bifidum can utilize all glycans 
attached to the glycosylated CMP except sialic acids; whereas B. longum can only utilize 
a minimal amount of the attached carbohydrate, since sialic acid is the terminal residue 
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of more than 70% of the glycan chains attached to a glycosylated CMP. CMP represents 
a source of carbon and nitrogen, thus its supplementation into the media was expected to 
enhance the growth (with the effect intensity in descending order) of B. infantis, B. 
bifidum, and B. longum.  
 
 
2 LITERATURE REVIEW 
 
2.1 Bifidobacterium spp. 
 
The first strain of Bifidobacterium spp. was isolated from infant feces at the 
beginning of the 20th century by Tissier and it was named as Bacillus bifidus (Shah, 
2002). The microbe had also been assigned to other genera such as Bacteroides, 
Lactobacillus and Corynebacterium over the years. It was not until 1960’s when 
bifidobacteria and lactobacilli were distinguished from one another based on, for 
instance, the presence of enzymes: fructose-6-phosphate-phosphoketolase was 
considered specific for bifidobacteria, whereas aldolase and glucose-6-phosphate 
dehydrogenase were considered specific for lactobacilli (Shah, 2002). The 
Bifidobacterium genus covers 32 species to date, five of which are substantially used in 
the dairy industry, namely B. adolescentis, B. bifidum, B. breve, B. infantis and B. longum 
(Shah, 2002).  
Bifidobacteria account up to 91% of the microbiota in newborns while representing 
3-7% in adults (Martinez et al., 2013). They are Gram-positive and non-spore forming 
bacteria. Most of them are catalase-negative and intolerant to oxygen. Bifidobacteria are 
mesophilic microbes where those of human origin proliferate most rapidly at 36-38°C. 
They grow optimally at pH 6.5-7.0 but hardly grow below pH 5.0 or above 8.0. The 
growth of Bifidobacterium spp. produces acetic acid and lactic acid, often in the ratio of 
3:2 (Shah, 2002).  
The technological aptitudes of the strains play an important role in determining their 
application in dairy products. For example, B. infantis ATCC 15697 and B. longum 
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ATCC 15707 are resistant to bile salt (Ibrahim & Bezkorovainy, 1993). This indicates 
that the strains can survive the exposure to bile salt in the small intestine and then 
populate in the colon. Although these strains barely survive in gastric pH (of around 2), 
but their survival rate increases when the pH is around 4 (Vernazza et al., 2005), which 
often occurs after the ingestion of a meal. Growth-promoting factors can also be added 
to the delivery medium (such as yogurt or cheese) to enhance their viability, and CMP 
is potentially one of them. Further elaboration can be found in Section 2.2. 
 
2.1.1 Health benefits of oral bifidobacteria administration 
 
Oral administration of bifidobacteria, for example, through the consumption of 
bifidobacteria-containing dairy products, can improve health in several ways as 
explained below. It should, however, be noted that the benefits are strain-specific.  
 
2.1.1.1 Production of antimicrobial compounds  
 
Bifidobacteria can help in controlling the population of pathogens in the 
gastrointestinal tract through the production of antimicrobial compounds. Bifidobacteria 
produce organic acids, particularly lactic acid, which lower the pH of the environment 
thereby inhibiting pathogens from localized colonization. Henriksson & Conway (2001) 
had also demonstrated that the strains LaftiTM B74 and LaftiTM B97 can inhibit the growth 
of Salmonella typhimurium.  
Bacteriocins are antimicrobial peptides that act against other bacteria but do not have 
an effect towards the producing organisms themselves. Few bifidobacterial isolates from 
infant stool, composing of B. longum, B. bifidum and B. adolescentis, have been shown 
to produce heat-stable proteinaceous compounds that were antagonistic against five to 
nine strains of Listeria monocytogenes (Touré et al., 2003). Bifidobacterium animalis 
subsp. lactis (B. lactis) Bb-12 and B. longum Bb-46 can produce bifilact Bb-12 and 
bifilong Bb-46, respectively, which were highly inhibitory against S. typhimurium, 
Staphylococcus aureus, Bacillus aureus and Escherichia coli (Saleh & El-Sayed, 2005). 
Bifidin I from B. infantis BCRC 14602 (same as ATCC 15697) is another example of 
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Bifidobacterium-associated bacteriocins. It was active against a wide range of Gram-
positive and Gram-negative bacteria, including L. monocytogenes LSD 346, S. aureus AS 
1.72, B. cereus ATCC 14574, E. coli TG1, and S. typhimurium ATCC 29631 
(Cheikhyoussef et al., 2010; Touré et al., 2003).  
 
2.1.1.2 Stimulation of immune function 
 
The dietary intake of fermented dairy foods containing bifidobacteria can modulate 
cellular function related to both natural immunity and acquired immunity. Consumption 
of B. lactis HN019 or B. lactis Bb-12 can enhance the phagocytic activity of leucocytes 
and macrophages in vivo (Gill et al., 2000; Schiffrin et al., 1997). Phagocytic activity of 
these immune cells plays an important role in removing pathogens and cell debris. 
Furthermore, antigen-specific antibody responses can also be stimulated after the 
ingestion of B. lactis HN019, leading to a rapid recovery from bacterial or viral infections 
(Gill et al., 2000; Shu et al., 2001).  
Research also showed that B. lactis HN019 can improve the activity of circulating 
natural killer (NK) cells, contributing to a better tumor surveillance in the body, among 
all advantages (Gill et al., 2001). An in vitro study has reported that B. bifidum LMG 
13195 can induce the secretion of chemokines and interferon molecules that recruit 
lymphocytes to fight against human colon cancer cells (López et al., 2012). Hence, dietary 
supplementation of bifidobacteria can result in an increased resistance to tumorigenesis, 
especially against colorectal tumors. Besides that, oral bifidobacteria administration can 
reduce the incidence and severity of inflammatory diseases via regulating the production 
of pro-inflammatory cytokines. Studies have concluded that B. longum NCC 2705 and B. 
breve Yakult strain have such an ability to regulate the functioning of T cells, 
consequently preventing intestinal inflammation or even ameliorating chronic 
inflammatory bowel diseases such as ulcerative colitis (Jeon et al., 2012; Zhang et al., 
2015). The oral intake of B. longum BB536 and B. lactis Bb-12 is also suggested to 
prevent allergic diseases. This is because they can inhibit immunoglobulin E (IgE) 
production, thereby lowering the allergen-induced immune responses such as hay fever 
(Feleszko et al., 2007; Takahashi et al., 2006).  
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Apart from that, high daily intake of bifidobacteria such as B. lactis HN019 and B. 
longum BB536 for a period of time can positively modulate the colonic microbiota, 
relieving the severity of gastrointestinal disorders (Miglioranza et al., 2015). An example 
of such health problem is lactose intolerance. Lactose intolerance is related to the 
incomplete digestion of lactose and inefficient colonic processing of the lactose 
metabolites. Despite that bifidobacteria cannot improve the lactose digestion in the small 
intestine, they flourish in the colon following a regular lactose ingestion (He et al., 2007). 
Thus, bifidobacteria are present at a higher number in the colon, in addition to an 
adaptation to lactose consumption (Hertzler & Savaiano, 1996). This indicates that more 
lactose can be hydrolyzed by the bacteria and the colon can absorb the fermentation 
metabolites more efficiently, and consequently alleviating the gastrointestinal symptoms 
such as diarrhea (He et al., 2006).  
 
2.1.1.3 Improvement in lipid profile 
 
The ingestion of bifidobacteria can improve the serum lipid profile of the consumer. 
For instance, the total serum cholesterol and low-density lipoprotein cholesterol of 
patients with metabolic syndrome or hypercholesterolemia had significant decrease after 
a daily intake of B. lactis HN019 or B. longum BL1 for a period of time (Bernini et al., 
2016; Xiao et al., 2003). It was proposed that the binding of cholesterol by the bacteria 
during cell proliferation lowers the absorption of cholesterol in the intestine. Another 
mechanism could be that the bifidobacteria produce hydrolase that deconjugate bile acid 
(Kim et al., 2004), resulting in a higher excretion of the free bile acid. Following this, the 
liver synthesizes new bile acid by drawing more cholesterol from the bloodstream. 
Furthermore, the fermentation of B. longum B1536 in soymilk can yield bioactive 
peptides with high inhibitory activity on angiotensin-I-converting enzyme (ACE) 
(Donkor et al., 2007). This means that the ingestion of the soymilk fermented with the 
strain can aid in regulating blood pressure, alongside with other health benefits.  
Apart from lowering the level of harmful lipid in the serum, bifidobacteria can also 
produce beneficial lipid molecules. B. breve NCFB 2258 and B. lactis Bb-12 are the most 
efficient generator of conjugated linoleic acid among the common bifidobacteria strains 
(Coakley et al., 2003). They convert the free linoleic acid from the growth environment 
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into conjugated linoleic acid, which inhibits atherogenicity and reduces body fat (West et 
al., 1998).  
 
2.1.1.4 Synthesis of B vitamins 
 
Bifidobacteria commonly synthesize B vitamins as metabolites. B. infantis ATCC 
15697 and B. adolescentis MB239 are the example of strains carrying an ability to 
synthesize folate (Pompei et al., 2007). The presence of folate-producing strains in the 
colon not only benefits the growth of other commensal bacteria, but also confers 
protection against colonic inflammation (Pompei et al., 2007; Said, 2011).  
Thiamin, nicotinic acid, pyridoxine, biotin and riboflavin can be synthesized by 
certain bifidobacteria strains. For example, B. adolescentis SI-30 synthesizes thiamin and 
nicotinic acid (Deguchi et al., 1985), and the biosynthesis pathways of thiamin and 
nicotinic acid have been completely identified in B. longum NCC2705 (Schell et al., 
2002). Most strains of bifidobacteria synthesize pyridoxine at a considerable 
concentration (Deguchi et al., 1985), whereas B. infantis I-10-5, B. bifidum A234-4, and 
B. longum M101-2 can produce different amounts of biotin depending on the types of 
oligosaccharides present in the media (Noda et al., 1994). Riboflavin is another B vitamin 
that can be synthesized at varied amount by bifidobacteria. Riboflavin content increased 
when soymilk was fermented with B. infantis CCRC 14633 or B. longum B6 (Hou et al., 
2000). However, this is inconsistent with the finding from Deguchi et al. (1985) where 
excess riboflavin was not detected in the media singly-inoculated by strains of B. infantis 
and B. longum. The discrepancy is most probably due to the different composition of 




2.1.1.5 Enhancement of nutrients bioavailability 
 
Studies have demonstrated that bifidobacteria can increase the level of amino acids, 
for instance leucine, during fermentation (Hou et al., 2000). This is resulted from the 
proteolytic activities of the organisms. Consequently, the food fermented by 
bifidobacteria has a better protein digestibility because more protein can be absorbed and 
utilized.  
Additionally, bifidobacteria possess β-glucosidase that hydrolyses soybean 
isoflavone glycosides into the corresponding aglycones which are better absorbed in 
human (Chen et al., 2011). Flavonols (such as kaempferol) and hydroxycinnamates (such 
as chlorogenic acid) that predominantly present in plant-based foods can also be 
metabolised into bioactive compounds by many strains of bifidobacteria (Marotti et al., 
2007; Raimondi et al., 2015).  
The ability of bifidobacteria to transform inorganic minerals into organic compounds 
(thus more bioavailable) has also been exhibited. As example, selenium is essential in 
proper functioning of enzymes. B. animalis 01 can convert inorganic selenium into an 
organic form known as selenomethionine, which is more absorbable by the human gut 
(Zhang et al., 2009). A daily intake of 50-60 µg selenium is recommended by the Nordic 
Council of Ministers, and the main dietary sources are meat and cereal products (Nordic 
Council of Ministers, 2012).  
 
2.1.1.6 Removal of hazardous compounds  
 
Bifidobacteria can reduce toxins and carcinogens in their growth environment. For 
instance, B. bifidum PTCC 1644 has shown to lower the aflatoxin B1, B2, G1 and G2 
produced by the toxigenic Aspergillus spp. (Ghazvini et al., 2016). This is attributed to 
the bifidobacterial cell wall which can effectively bind to the toxic molecules. Besides 
that, B. longum BB536 can exert antitumor protection by enhancing the activity of 
glutathione transferase, which efficiently transforms the carcinogens in the colon into less 
harmful conjugates (Challa et al., 1997).  
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Apart from that, bifidobacteria possess antioxidative activity too. Wang et al. (2006) 
had demonstrated that the soymilk fermented by B. infantis ATCC 27920 or B. longum 
B6 exerted higher reducing activity than unfermented soymilk. The reason behind this 
phenomenon is due to the antioxidative properties of the metabolites of isoflavones and 
the catabolism of proteins. Furthermore, the co-fermentation of L. acidophilus with either 
one of the abovementioned strains could enhance the reducing activity (thus, 
antioxidative activity) of the fermented soymilk even further.   
 
2.1.2 Growth requirements of bifidobacteria  
 
Generally, the growth requirements of bifidobacteria are fewer than the genus 
Lactobacillus. Bifidobacteria, in fact, are capable of the biosynthesis of some amino 
acids, vitamins, purines and pyrimidines (Gomes & Malcata, 1999; Sela et al., 2008). 
Many amino acids can be derived from carbohydrate intermediates. For example, 
glycine can potentially be synthesized from glycerate-3-phosphate, and tryptophan can 
potentially be synthesized from phosphoenolpyruvate (Lee & O’Sullivan, 2010). 
Nevertheless, cysteine is an indispensable amino acid for most bifidobacteria (Ferrario 
et al., 2015).  
Although bifidobacteria are not nutritionally fastidious, they do not grow well in milk 
because the concentration of small peptides and amino acids in the milk (approximately 
0.1 g/L) is insufficient for their growth (Gomes & Malcata, 1999). Thus, proteolytic 
starter cultures such as L. delbrueckii subsp. bulgaricus and Streptococcus thermophilus 
are often used to initiate the fermentation in milk, and Bifidobacterium spp. is then 
incorporated at a later stage.  
The ability to ferment carbohydrate is species- and even strain-specific. Table 1 
displays the carbohydrates fermentability of B. infantis ATCC 15697, B. bifidum ATCC 
29521 and B. longum ATCC 15707. Generally, hexoses (such as glucose), 
oligosaccharides (such as fructooligosaccharides), and polysaccharides (such as 




Table 1. Carbohydrate fermentation profile of B. infantis ATCC 15697, B. bifidum ATCC 29521 and B. 




















B. infantis ATCC 15697 + + - + - 
B. bifidum ATCC 29521 - + + + - 
B. longum ATCC 15707 - - - + + 
+ : fermentable.            
- : non-fermentable. 
 
A minimal medium for bifidobacteria has been developed by Hassinen et al. (1951). 
By starting with a complete chemically-defined medium, the removal of thiamin, 
riboflavin, nicotinic acid, pyridoxine, folic acid, p-aminobenzoic acid, adenine, guanine, 
uracil and xanthine, alone or in combination, from the medium did not decrease the 
bifidobacterial growth. Whereas the removal of a salt solution containing MgSO4.7H2O, 
FeSO4.7H2O, NaCl, and MnSO4.H2O reduced the bifidobacterial growth, and individual 
elimination of any of the minerals had no effect on growth. The researchers consequently 
summarized that the tested bifidobacterial strains isolated from the stools of breast-fed 
infants would grow on a medium comprised of a fermentable carbohydrate (lactose), 
buffers (sodium acetate and dipotassium phosphate), minerals (in the form of the 
abovementioned salt solution), ammonium salts (ammonium acetate), cysteine as well 
as B vitamins (biotin and calcium pantothenate).  
As demonstrated in several studies, exogenous B vitamins are required for normal 
growth of bifidobacteria. While biotin and calcium pantothenate have been shown 
indispensable for growth of Birch strain, Lockhart strain, Timberlain strain and Perrish 
strain (Hassinen et al., 1951), thiamin and nicotinic acid are essential for maximal growth 
in majority of the strains of B. adolescentis (Deguchi et al., 1985). Riboflavin can also 
be dispensable or indispensable for bifidobacteria. B. infantis ATCC 15697 can synthesis 
riboflavin, so the nutrient acts only as a growth stimulant for this strain (Sela et al., 2008), 
but it may be required for the growth of B. adolescentis (Deguchi et al., 1985).  
Hence, the differences of growth requirements among B. infantis ATCC 15697, B. 
bifidum ATCC 29521 and B. longum ATCC 15707 possibly lay on biotin, calcium 
pantothenate, thiamin, nicotinic acid, and riboflavin.   
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2.1.3 B. infantis ATCC 15697 
 
This type strain has the synonym names of S12, DSM 20088, and JCM1222 (NCBI, 
n.d.). Its guanine-cytosine content is 60.5 mol% (Mattarelli et al., 2008).  
This strain is only present in human infant, typically in the intestines (Matsuki et al., 
1999). It is genetically adapted to metabolize the nutrients in human milk (Ward et al., 
2007). It utilizes sialylated and fucosylated oligosaccharides in the human milk through 
the cooperation of a wide array of permeases, extracellular carbohydrate-binding 
proteins, and glycoside hydrolases (Desjardins & Roy, 1990; Shah, 2002). One of the 
glycoside hydrolases is exo-α-sialidase, which is the enzyme that removes terminal sialic 
acid residues from a glycan chain (Kiyohara et al., 2011).  
 
2.1.4 B. bifidum ATCC 29521 
 
This type strain has the synonym names of Tissier 1900, JCM1255, DSM 20456, and 
LMG 11041 (NCBI, n.d.). The guanine-cytosine content is 61 mol% (Whitman et al., 
2012).   
The variant b of B. bifidum ATCC 29521, which was used in this project, 
predominates in the feces of human infants (Ventura et al., 2003; Whitman et al., 2012). 
Although no sialidase has ever been isolated from this strain, it exhibits sialic acid-
degrading activity where sialic acids can be cleaved from sialylated glycan chains but 
are left unutilized (Milani et al., 2015; Ward et al., 2007). Additionally, the strain also 
produces endo-α-N-acetylgalactosaminidase, which is the enzyme that removes 
GalNAc-containing disaccharides from the polypeptide backbone in a glycoprotein 





2.1.5 B. longum ATCC 15707 
 
This type strain has the synonym names of E194b (variant a), DSM 20219, 
JCM1217, and LMG 13197 (NCBI, n.d.). The guanine-cytosine content is 61 mol% and 
has a large variety of plasmids (Mattarelli et al., 2008).   
It predominantly colonizes in the colon and can be isolated from the feces of human 
infant or adult (Ventura et al., 2003), though the type strain used in this project originated 
from adult. The strain possesses endo-α-N-acetylgalactosaminidase but does not have 
exo-α-sialidase (Fujita et al., 2005; Kiyohara et al., 2011).  
 
2.2 Growth-promoting effect of caseinomacropeptide (CMP) on bifidobacteria 
 
2.2.1 CMP as carbon and nitrogen sources  
 
Apart from the co-inoculation with proteolytic starter cultures, it is a usual practice 
to add growth-promoting factors, such as whey protein permeate, into the milk during 
fermentation to improve the growth of Bifidobacterium spp. (Shah, 2002). This is not 
only due to the extra source of nitrogen in the form of small peptides and amino acids, 
but also due to the associated glycans including sialic acid (Modler, 1993).  
However, enzymes availability of bifidobacteria vary from strain to strain. For 
example, B. infantis ATCC 15697 grew rapidly in the medium containing N-linked 
glycoproteins from bovine colostrum whey, but did not grow in deglycosylated milk 
protein fraction; whereas B. lactis UCD316 did not grow in either medium (Karav et al., 
2016). This implies that B. infantis can synthesize the enzyme known as endo-β-N-
acetylglucosaminidase (endoBI-1) which enables the cleavage of N-linked glycan 
chains, thereby using them as substrates for growth; but the enzyme is absent in B. lactis.  
Bovine CMP has exhibited growth-promoting effect on B. infantis S12 (same as 
ATCC 15697) in the study conducted by Azuma et al. (1984). The finding was inferred 
from the higher level of titratable acidity in CMP-supplemented group than in 
unsupplemented group after 24 hours of incubation. They proposed that both the 
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polypeptide moiety (which refers to the CMP backbone) as well as the attached glycans 
play the role in enhancing the bifidobacterial growth. Nonetheless, the growth-promoting 
effect of bovine CMP was about four times weaker than human CMP, probably because 
of the lower carbohydrate content in the former (Azuma et al., 1984; Yamauchi et al., 
1981).  
A similar finding was obtained when the rennet whey fraction of the bovine milk 
supported an extended growth of B. bifidum ATCC 11863, B. bifidum ATCC 15696, B. 
breve ATCC 15700, B. infantis ATCC 15697, and B. longum ATCC 15708 in the study 
carried out by Petschow & Talbott (1990). It was deduced from the significantly higher 
total acidity after 48 hours of incubation in the rennet whey-supplemented group as 
compared to the control group. Besides that, bovine CMP also enhances the growth of 
B. lactis DSM 10140. This was evidenced by the higher viable counts and lower pH after 
6- and 24-hour incubation in the medium supplemented with bovine CMP in comparison 
to the unsupplemented group (Janer et al., 2004).  
 
2.2.2 CMP as nitrogen source 
 
Nevertheless, the effectiveness of the carbohydrate moiety of the CMP to enhance 
bifidobacterial growth is not definitively established. Robitaille (2013) noticed that the 
growth rate of B. thermophilum RBL67 was similar in the medium supplemented either 
with bovine highly-glycosylated CMP, or non-glycosylated CMP, or CMP (a mixture of 
both). The researcher therefore concluded that CMP contributes to the bifidobacterial 
growth merely due to the polypeptide itself.  
Poch & Bezkorovainy (1991) reported a similar phenomenon. They investigated the 
growth-promoting activity of trypsin-digested bovine milk where the turbidity of the 
media was compared after 24 hours of incubation. The researchers found out that the 
medium supplemented with the para-κ-CN enhanced the respective growth of B. bifidum 
ATCC 15696 and B. longum ATCC 15708 at a larger intensity than the effect exerted by 
supplementing the medium with the CMP. Therefore, they denied the importance of the 
carbohydrate portion in CMP. They instead pointed that the presence of 
disulfide/sulfhydryl residues as well as a yet-to-be-identified factor in the para-κ-CN that 
play the growth-promoting role. It is noteworthy that the CMP used in their study was 
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prepared by using trypsin, an enzyme that hydrolyses κ-CN at Lys111, Lys112 or Lys116 
(Bouhallab et al., 1993), thus yielding different peptides than the CMP prepared by 
chymosin.  
Apart from that, sialic acids in the glycosylated CMP were claimed not to be the 
reason behind its growth-stimulation on bifidobacteria. The inoculation of B. infantis 
ATCC 15697 and B. bifidum ATCC 29521, respectively, into a broth supplemented with 
0.01 mg/mL of glycosylated CMP (containing approximately 0.6 µg sialic acid/mL) had 
significantly higher growth rates than the supplementation of glycosylated CMP at 1.0 
mg/mL (Idota et al., 1994). Another study reported a similar finding where the sialic acid 
content of glycosylated CMP did not have a direct relationship with growth-promoting 
effect on B. lactis Bb-12 and B. longum BBMN68 (Tang et al., 2013).  
 
2.3 Source of bovine CMP 
  
About 3.5% (w/w) of bovine milk is protein (Heck et al., 2009). Casein accounts for 
approximately three quarters of the total protein whereas whey protein constitutes the 
remaining proportion. There are four major types of casein, namely α-, β-, κ-, and γ-
casein. K-casein (κ-CN) takes up about 8% of the casein family.  
K-CN is composed of 169 amino acids. Upon the addition of rennet (an enzyme 
preparation) into the milk during cheese-making, chymosin in the rennet cleaves the 
bond between Phe105 and Met106 of the κ-CN, yielding two peptides – CMP, which is 
released to the liquid (known as “rennet whey” subsequently in this project), and para-
κ-CN, which is hydrophobic and remains in the curd (Delfour et al., 1965). The former 
is a polypeptide composed of 64 amino acids from the carbon terminal of κ-CN, which 
is starting from Met106 until Val169. Among the 20 common amino acids, six of them are 
absent in CMP, namely histidine, arginine, cysteine, and the aromatic amino acids – 
phenylalanine, tyrosine, and tryptophan. The two most common allelic variants of κ-CN 
are A and B. They differ from one another at the amino acid positions 136 and 148 





Figure 1. Structure of CMP variant B with the potential glycosylation sites underlined [modified from 
Thomä-Worringer et al., 2006]. The positions of the amino acid residues in the κ-CN are given 
in parentheses. Amino acid substitutions in CMP variant A are given in brackets.  
 
2.4 Glycosylation of bovine CMP 
 
Almost all proteins synthesized in eukaryotic cells undergo post-translational 
modifications to properly perform their molecular functions (Blom et al., 2004). 
Glycosylation is one of the common modifications.  
The building blocks of the glycan chains in glycosylated CMP are galactose (Gal), 
N-acetylgalactosamine (GalNAc), and N-acetylneuraminic acid (NeuNAc) (Manso & 
López-Fandiño, 2004). NeuNAc is more commonly known as “sialic acid”, therefore the 
latter term will be used subsequently in this project. The glycosylation of a CMP is 
initiated by attaching a GalNAc residue to the hydroxyl group (OH-) of a Ser or Thr 
residue via an O-linkage, which is catalyzed by the enzyme UDP-GalNAc:polypeptide 
N-acetylgalactosaminyl transferase (GalNAcT) (Holland et al., 2005). On the other hand, 
the attachment of a carbohydrate residue to the amino group (NH2) of an Asn residue is 
known as N-linked glycosylation. It is, however, only found in other fractions of the 
bovine mature milk, for instance lactoferrin in the whey.  
Six glycosylation sites have been proposed, of which all are Thr residues (Figure 1) 
(Pisano et al., 1994). This finding disagreed with an earlier study conducted by Zevaco 
& Ribadeau-Dumas (1984) which showed that the CMP glycosylation can also occur at 
Ser141. The number of glycan chains attached to one CMP backbone can vary from one 
to five (Abd El-Salam et al., 1996; Dziuba & Minkiewicz, 1996). The glycosylation of 
a CMP was initially suggested to occur by a random mechanism (Fiat et al., 1988). 
However, newer research has found out that the process occurs with consistent patterns 
(Coolbear et al., 1996). The primary glycosylation site occurs at Thr131 (Holland et al., 
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2005), but Thr133 as the primary glycosylation site has also been proposed (Hua et al., 
2012). Despite that, either Thr131 or Thr133 must be the primary site because of the 
technical difficulty in distinguishing between them (Hernandez-Hernandez et al., 2010).  
The glycan chains attach to a CMP molecule can be in five arrangements (Figure 2). 
The most abundant type of chain is tetrasaccharides (56.0%), followed by trisaccharides 
(18.5% for branched-chain; and 18.4% for straight-chain), disaccharides (6.3%), and 
lastly monosaccharide (0.8%) (Saito & Itoh, 1992). The occurrence of two isomers of 
the trisaccharides can be explained by the presence of two types of sialyltransferases in 
the mammary epithelial cells. One or two sialic acid residues are present at the terminals 
of the trisaccharides or tetrasaccharides chain as depicted in Figure 2. In other word, 









CMP variant B is generally more glycosylated than variant A (Coolbear et al., 1996). 
The postulated reason for this phenomenon is that the presence of Thr136, instead of Ile136, 
in variant A modifies the conformation of the molecule, thereby reducing the efficiency 
of glycosylation process by GalNAcT in the mammary epithelial cells (Robitaille et al., 
1991). The degree of glycosylation, as reflected by the sialic acid content in κ-CN, is 
highest in colostrum, decreases a little in the first 2-3 months and then increases again 
with progressing lactation (Robitaille et al., 1991). Nonetheless, three-fifth of CMPs is 
glycosylated in average (O’Riordan et al., 2014).  
 
2.5 Isolation of bovine CMP  
 
CMP is very polar due to its amino acid composition as well as the attached glycan 
chains (Yvon et al., 1994). Thus, it is highly soluble in aqueous solutions. The isoelectric 
point of CMP is around pH 4.0, but can be as low as pH 3.15 when the CMP contains 
higher number of sialic acid residues (Kreuβ et al., 2009). Based on these characteristics, 
several methods have been developed to isolate CMP. A combination of methods is 
required to enhance the purity of the product. 
 
2.5.1 Selective precipitations 
 
Milk samples are generally treated with chymosin to release CMPs into the rennet 
whey. Following that, the selective precipitation is done by adding trichloroacetic acid 
(TCA) into the rennet whey to precipitate proteins other than CMP, subsequently dialysis 
and lyophilization of the supernatant. However, one disadvantage of this approach is that 
a lower degree of glycosylation results in lower solubility in TCA. For instance, the final 
concentration of 120 g/L TCA precipitates non-glycosylated CMPs and therefore leading 
to reduced recovery rate (Vreeman et al., 1986).  
Another approach is through the alcohol precipitation after a heat treatment (Saito et 
al., 1991). Rennet whey, which has been adjusted to pH 6.0, is first heated at 98°C for 
one hour before added with cold 50% (v/v) ethanol. The heat treatment coagulates whey 
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proteins and the addition of ethanol precipitates them. Likewise, it is followed by 
lyophilization of the supernatant. 
 
2.5.2 Ultrafiltration techniques 
 
Another means of isolating CMP is through ultrafiltration. CMP (variant A) has the 
molecular mass of 6.7 kDa (Jollès et al., 1972), whereas highly glycosylated ones is 
approximately 9.6 kDa (Mollé & Léonil, 2005).  
The preparation of CMP at an industrial scale often employs ultrafiltration technique 
because it offers the advantage of obtaining a product with higher quality and purity. The 
best example is the CMP product commercialised by Arla Foods Amba (Denmark) 
which is protected by a patent. The process is unique because a large yield of pure 
product can be obtained at low operating costs without noticeable denaturation (Holst & 
Chatterton, 2002). The main processing steps include acid precipitation preceding to the 
ultrafiltration at 12°C using a membrane that has a cut-off value of 20 kDa.  
It is interesting to note that the apparent molecular weight of the CMP can change 
owing to pH-induced aggregation during the enzymatic cleavage of the κ-CN. Mikkelsen 
et al. (2005) had demonstrated that the chymosin or pepsin hydrolysis of κ-CN 
performed at pH 6.6 resulted in aggregated CMP units with an apparent molecular weight 
of 35 kDa. Contrarily, the enzymatic hydrolysis of the κ-CN carried out at pH 2.5 or 3.4 
resulted in both aggregated and monomeric forms of CMP, which can have the apparent 
molecular weights of 9, 18, and 35 kDa. The probable reason is that at pH 6.6, κ-CN 
molecules tend to bind to adjacent molecules more tightly, for instance, by crosslinking 
via disulphide bonds at Cys11 and Cys88. This in turn increases the association of CMP 
units. Whereas in an acidic environment, κ-CN molecules are less associated with one 
another. Despite that, the apparent molecular weight of CMP is stable against pH changes 






2.5.3 Chromatographic techniques 
 
Ion-exchange chromatography is by far the most popular technique used in purifying 
CMPs, whereas gel chromatography and hydrophobic interaction chromatography are 
the alternative choices (Nakano & Ozimek, 2000; Silva-Hernandez et al., 2002). 
CMP remains negatively charged in an acidic environment while other whey proteins 
are positively charged (Kreuβ et al., 2009). Thus, after adjusting the rennet whey to pH 
4 and subjecting to an ion-exchanger resin, main whey proteins will adsorb on the resin 
and separate from the filtrate fraction which contains CMPs (Kawasaki et al., 1994). The 
filtrate fraction can then be collected and concentrated. The separation of glycosylated 
from non-glycosylated fractions of CMP is also possible by using anion-exchange 
membrane adsorption chromatography (Robitaille, 2013). A variation succeeding the ion 
exchange is the use of a peanut lectin agglutinin (PNA) column to fractionate 
glycosylated CMP into sialylated and non-sialylated portions (Saito et al., 1991).  
 
 Quantification of glycosylated CMP 
 
The quantification of glycosylated CMP can be determined chromatographically or 
colorimetrically. While the general principle of the chromatography has been described 
in Section 2.5.3, the presence of sialic acids in glycosylated CMP forms the basis of the 
colorimetric methods. Sialic acid, an acylated nine-carbon molecule (Figure 3), is the 
condensation product of one pyruvic acid residue and one N-acetyl-D-mannosamine 
residue (Warren & Felsenfeld, 1962). Sialic acid reacts with specific reagents to form a 
chromophore (colored compound) and the color intensity is directly proportional to its 
concentration. Table 2 displays the colorimetric assays that are commonly used to 
quantify sialic acid.  
 
 
Figure 3. Structure of a sialic acid [adapted from O’Kennedy, 1988].  
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Pros Cons References 
Thiobarbituric acid (TBA) 
 
Main reagents:  
Sodium periodate, phosphoric 
acid, 2-thiobarbituric acid, 
cyclohexanone 
 
Absorbance: 549 nm 
 
 
• Reproducible results 
• Sensitive 
• Measure free sialic 
acid contents 
 








Main reagents:  
Solution with ferric ions, 
hydrochloric acid, orcinol, 
isoamyl alcohol 
 
Absorbance: 570 nm 
 
 
• Rapid test 
 
• Interference by 
glucose and 
fructose 
• Only measure 






Main reagents:  
Solution with cupric ions, 
resorcinol 
 
Absorbance: 588 nm 
 
 
• Rapid test 
• More sensitive than 
orcinol assay 
 
• Less sensitive 
than TBA assay 
• Only measure 











Absorbance: 565 nm 
 
 
• Color (chromophore) 
is stable 
 
• Less sensitive 
than TBA assay 
• Only measure 







Main reagents:  
A mixture of sialidase, sialic 




• 340 nm (if oxidize the 
pyruvate by using lactate 
dehydrogenase) 
• 630 nm (if oxidize the 









Muniandy et al., 
2005 
Acidic ninhydrin  
 
Main reagents:  
Ninhydrin, glacial acetic acid, 
hydrochloric acid, ethanol 
 
Absorbance: 470 nm 
 
 
• Rapid test 
• Specific 
• Simple test 
 








2.6.1 High-performance liquid chromatography (HPLC) 
 
The most common chromatographic instrument used for the quantification of 
glycosylated CMP is by using the high-performance liquid chromatography (HPLC). 
The European Commission has laid down a HPLC method for the determination of 
glycosylated CMP as part of the effort to detect the addition of rennet whey in skimmed 
milk powder (European Commission, 2008).  
A reversed-phase HPLC is required to perform the analysis. The eluents often consist 
of acetonitrile, isopropanol, and trifluoroacetic acid. Principally, the method involves 
selective precipitation by TCA to remove fat and proteins from the specimen prior to the 
injection into the HPLC. The molecular mass of the isolated peptides can further be 
identified by coupling the HPLC with a mass spectrometer. Nevertheless, 
chromatographic method is generally more sophisticated and laborious than the 
colorimetric methods, particularly acidic ninhydrin method. 
 
2.6.2 Acidic ninhydrin method 
 
Acidic ninhydrin method has served as a routine screening method for detecting milk 
adulteration in Brazil since 2003 (Fukuda et al., 2004). Although this method is 
commonly used for quantifying amino acids such as tryptophan, cysteine and tyrosine 
(Figure 4 displays the absorption spectra of the related chromophores), but it can also be 
used to quantify sialic acids where the results can be as reliable as those obtained from 
the HPLC method published by the European Commission (Fukuda et al., 2004; Yao & 





Figure 4.  Absorption spectra of the chromophores formed between tryptophan, cysteine and tyrosine with 
the ninhydrin reagent [modified from Bao et al., 2006]. The maximum absorption of the sialic 
acid-formed chromophore, 470 nm, is marked in purple. 
 
Acidic ninhydrin method involves the use of TCA to first selectively solubilize the 
glycoproteins that carry sialic acid residues, followed by the precipitation using 
phosphotungstic acid and ethanol (Inoue et al., 1998; Patt & Grimer, 1974). Finally, the 
reaction between the acidic ninhydrin reagent with the sialic acids in the precipitate 
yields chromophores which have the absorption maximum at 470 nm. A duration of two 
hours is sufficient to complete the whole procedure, which is less time-consuming as 
compared to the HPLC method.  
 
 
3 MATERIALS AND METHODS 
 
3.1 Source of the bifidobacterial cultures  
 
Freeze-dried B. infantis ATCC 15697, B. bifidum ATCC 29521, and B. longum 
ATCC 15707 were purchased from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ), Germany. All three strains were grown overnight in sterilized de 
Man-Rogosa-Sharpe (MRS) broth (Oxoid, UK; prepared as stated on the label) 
supplemented with sterile-filtered 0.5 g/L L-cysteine.HCl monohydrate (Sigma, Japan) 
in 15mL-Greiner tubes. Then, 0.7 mL of the respective overnight culture was mixed with 
0.3 mL of the 99% glycerol (Sigma, Germany) (thus, final glycerol concentration of 
Sialic acid  
32 
 
30%) in 1.5mL-cryo vials. All cryo vials were immediately stored in a -46°C freezer and 
served as the stock cultures.  
Strains were activated by growing three successive times in sterilized MRS broth 
supplemented with sterile-filtered 0.5 g/L L-cysteine.HCl monohydrate in 15mL-Greiner 
tubes. The transfer volume from the stock cultures was 0.2% (v/v). Following that, 1% 
(v/v) was transferred to a new MRS broth each time. Incubation for B. longum was done 
at 37°C for 16 hours, and 24 hours for B. infantis and B. bifidum.  
 
3.2 Preparation of the inocula 
 
1 mL of each overnight culture was centrifuged (5430R, Eppendorf, Germany) in a 
pre-sterilized 1.5mL-Eppendorf tube at 10000 rpm for 5 minutes at 4°C. The supernatant 
was discarded and the cell pellet was re-suspended in an equal volume of phosphate-
buffered saline (PBS; the composition was 2.71 g/L NaH2PO4.2H2O, 8.98 g/L 
Na2HPO4.2H2O, 8.5 g/L NaCl, and 1 L demineralized water which was adjusted to pH 
7.2 before autoclave). This step is also known as “washing”. The cell pellet was washed 
twice before the third PBS+cell suspension was diluted with PBS to OD600nm 0.10-0.35. 
The OD was measured using a UV-Vis spectrophotometer via its fiber optic dip probe 
(Varian Cary 50 Bio, Agilent, USA). The suspension, which was equivalent to 
approximately 107 cfu/mL at this stage, was then used as the inoculum for the preparation 
of bCDM and the first part of the growth experiments.  
Meanwhile, the cell count was determined by spread-plating on a MRS agar plate 
[MRS + 15 g/L bacteriological agar (Oxoid, UK) + 0.5 g/L sterile-filtered L-
cysteine.HCl monohydrate]. Serial dilution was performed using physiological salt 
solution (PFZ; Tritium Microbiologie, the Netherlands). Incubation of the agar plates 
was done at 37°C in an air-tight jar filled with anaerobic gas mixture (85% N2, 10% CO2, 
5% H2) using Anoxomat WS9000 (Mart Microbiology, the Netherlands). Additional 






3.3 Preparation of a basal chemically-defined medium (bCDM) 
 
A bCDM, which was devoid of carbon and nitrogen sources, was employed to 
investigate the utilization of bovine glycosylated CMP by the strains. Preliminary 
experiments were conducted to decide the most suitable formula.  
 
3.3.1  Preliminary experiments 
 
A very basic formula of bCDM (Table 3) and a list of potentially indispensable 
nutrients were created by referring to the literature. Carbon (predetermined as D-
glucose) and nitrogen sources were temporarily added to ensure that the bCDM can 
support the growth of the three strains. The base bCDM was sterilized by autoclave 
(except L-cysteine.HCl monohydrate which was sterilized by filtration) and served as 
the control. 
 







K2HPO4.3H2O  2.0 
L-cysteine.HCl.H2O 0.5 
MgSO4 0.2 
MnSO4.H2O  0.1 
Bromocresol purple 0.03 
(Demineralized water) (1 L) 
 
Eight nitrogen sources were tested for suitability by adding into the base bCDM at 
single addition. After single-strain inoculation with the suspension prepared in Section 
3.2 followed by an overnight incubation, the optimum nitrogen source was selected and 
proceeded to the subsequent step.  
In the subsequent experiment, six B vitamins and four nucleobases were added into 
the base bCDM either at single addition or in combination to distinguish the 
indispensable nutrient from non-indispensable ones. Similarly, after single-strain 
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inoculation followed by incubation, the nutrient or combination of nutrients that 
supported the growth of the strains was identified. The base formula of the bCDM was 
then finalized by omitting the carbon and nitrogen sources.  
  
3.3.2 Finalized composition  
 
The finalized composition of the bCDM is listed in Table 4 together with the 
preparation details. Chemicals were obtained from Sigma (Germany) unless otherwise 
specified.  
 








pH of the solution was adjusted to pH 7.5 before sterilization by autoclave  
(121°C; 15 minutes): 
 
NaCl 5.0 
K2HPO4.3H2O * 2.0 
MgSO4 0.2 
MnSO4.H2O * 0.1 
Bromocresol purple 0.03 
(Demineralized water) (1 L) 
 
Sterilization by disk filtration (pore size 0.20 µm; Phenex, the Netherlands): 
 
L-cysteine.HCl.H2O 0.5 
Thiamin.HCl (for B. bifidum only) 0.004 
Nicotinic acid (for B. bifidum only) 0.002 
   * Merck, Germany 
 
3.4 Growth experiments 
 
The bCDM and MRS broths were used in the first and second parts of the growth 
experiments, respectively. The latter medium was employed to investigate the growth-
promoting effect of CMP.  
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In the first part of the growth experiments, bCDM was adjusted to pH 6.6 ± 0.1 before 
transferring 10 mL into a 15 mL-Greiner tube in duplicate. One group of tubes was 
supplemented with 10.0 g/L sterile-filtered CMP (Lacprodan CGMP-20; Arla Foods 
Amba, Denmark), and another group of tubes was added with equal volume of 
demineralized water as the control. Both groups were inoculated with 10% (v/v) of the 
PBS+cell suspension. One negative control (non-inoculated) was prepared for each 
group by adding equal volume of PBS. The tubes were subsequently incubated at 37°C 
for 38 hours. At the end of the incubation period, the final cell counts were determined 
by spread-plating as described in the last paragraph of Section 3.2. Additionally, the 
bound sialic acid contents were quantified as described in Section 3.5. 
In the second part of the growth experiments, inocula with lower cell counts were 
prepared by twice diluting 1 mL of respective PBS+cell suspensions having the OD600nm 
0.10-0.35 (Section 3.2) with 99 mL of PBS. MRS broth, prepared as stated on the label, 
was adjusted to pH 7.0 prior to autoclave. After that, it was supplemented with 0.5 g/L 
sterile-filtered L-cysteine.HCl monohydrate and adjusted to pH 6.2 ± 0.1 before use. The 
subsequent steps were similar as in the first part of the growth experiments, except that 
the tubes in the test group were added with 1.5 g/L of CMP and inoculated with lower 
cell counts, and finally all tubes were incubated at 37°C for 22 hours. Figure 5 displays 
















Figure 5.  Experimental flow chart. 
 
3.5 Sialic acid quantification by acidic ninhydrin method 
 
The method was adapted from Fukuda et al. (2004) with modification. All chemicals 
were of analytical grade. All samples were analyzed in duplicate.  
 
3.5.1 Preparation of the standard curve  
 
The molecular mass of sialic acid is 309.27 g/mol. A stock standard of 100mM (100 
nmol/µL) sialic acid was prepared by dissolving 0.0030 g of pure sialic acid powder 
(Carbosynth, UK) in 0.1 mL of MilliQ water (purified by Purelab Ultra, Elga, USA). It 







Inoculation of the media 
 
Groups Specimens 
Control B. infantis B. bifidum B. longum 
Unsupplemented bCDM or MRS     
10.0 g/L CMP in bCDM; or  
1.5 g/L CMP in MRS 
    
 
Preparation of the inocula 
 
Initial cell counts 
 
MRS broth, pH 6.2 ± 0.1 
(growth-promoting effect of CMP) 
 
bCDM, pH 6.6 ± 0.1 














1mM and 10mM sialic acid standard solutions were freshly prepared using the stock 
standard and MilliQ water as the diluent. From these standard solutions, 1.5mL-
Eppendorf tubes were respectively filled with 0, 5, 10, 20, 50, 100, 200, and 500 nmol 
sialic acid. All tubes were added with 0.2 mL of pure glacial acetic acid (Merck, 
Germany) and 0.1 mL of acidic ninhydrin reagent. The latter reagent was prepared by 
dissolving 1.0 g of ninhydrin crystals (Sigma, Germany) in 16 mL of 37% (w/w) 
hydrochloric acid (AnalaR, the Netherlands) and 24 mL of pure glacial acetic acid.  
Subsequently, the Eppendorf tubes were vortexed thoroughly, and heated at 100°C 
for 10 minutes using a heating block (QBT4, Grant Instruments, UK). The tubes were 
chilled on ice prior to topping up to exactly 1.0 mL with absolute ethanol (Merck, 
Germany). The tubes were vortexed immediately before measuring the OD470nm with a 
spectrophotometer. A standard curve of sialic acid was finally plotted.  
 
3.5.2 Analysis of the samples 
 
At the end of the incubation period of the growth experiments, the tubes were 
centrifuged at 4700 rpm for 5 minutes at 4°C. 2 mL of each supernatant was mixed with 
2 mL of 240 g/L trichloroacetic acid (TCA) (Merck, Germany) and allowed to stand for 
30 minutes. The solution was filtered through a disk filter (0.20 µm pore size) before 1 
mL of the filtrate and 0.1 mL of 200 g/L phosphotungstic acid hydrate (Sigma, Germany) 
were filled into an 1.5mL-Eppendorf tube. After a centrifugation at 3500 rpm for 10 
minutes at 20°C, the supernatant was gently discarded and 0.6 mL of 95% (v/v) ethanol 
(prepared from absolute ethanol) was added to the precipitate. Centrifugation was done 
once again with the same parameters and the supernatant was also gently discarded.  
Like the standard solutions, 0.2 mL of pure glacial acetic acid and 0.1 mL of acidic 
ninhydrin reagent were then added into each tube in which containing precipitates at this 
stage. Next, the Eppendorf tubes were vortexed thoroughly, heated at 100°C for 10 
minutes, chilled on ice, topped up to exactly 1.0 mL with absolute ethanol, and vortexed 
again. Following that, another centrifugation at 3500 rpm for 5 minutes at 20°C was 
carried out. The OD470nm of each tube was finally measured with a spectrophotometer. 
The number of moles (nmol) of sialic acid in the respective tube was obtained by using 
the equation generated from the standard curve. The bound sialic acid content (g/L) was 
calculated with Equation 1. 
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Equation 1:  
 






n = number of moles (nmol); obtained from the equation of the standard curve 
M = molecular mass of sialic acid (g/nmol); 3.0927 x 10-7 g/nmol in this case 
V = volume of solution (L); 10-4 L in this case 
 
3.5.3 Spike test 
 
A CMP assay with the final concentration of 2 g/L was prepared with bCDM and 
treated the same as described in Section 3.5.2 without the centrifugation step in the very 
beginning. Before heating at 100°C, 0.05 mL of 1mM sialic acid standard solution (thus, 
50 nmol sialic acid) was added into three ‘spike’ tubes (triplicate). One control was 
prepared as ‘original’ tube. The recovery yield (%) was then calculated with Equation 2.  
 
Equation 2:  
 
Recovery yield (%) =  
Ck− Co
Cs
×  100% 
where, 
 
Ck = bound sialic acid content of the spiked sample (g/L) 
Co = bound sialic acid content of the original sample (g/L) 
Cs = amount of sialic acid intentionally added (g/L) 
 
The percentage of bound sialic acid content in the medium and in the CMP (% w/v) 




% (w/v) of bound sialic acid in the medium =  
𝐶𝐶𝑀𝑃− 𝐶
V






% (w/v) of bound sialic acid in the CMP =  
𝐶𝐶𝑀𝑃− 𝐶
𝑚𝑖
×  100%  
where, 
 
CCMP = bound sialic acid content in the non-inoculated, CMP-supplemented medium (g/L) 
C = bound sialic acid content in the non-inoculated, unsupplemented medium (g/L) 
V = volume of solution (mL); 1000 mL in this case 
mi = concentration of the CMP supplemented into the medium (g/L) 
 
3.6 Data and statistical analyses 
 
The mean values and standard deviations of bound sialic acid contents and cell counts 
were computed using Equations 5 and 6, respectively. The mean values were used for 
comparison among the specimens and between the groups, whereas the standard 
deviations were used to determine the precision of the results. One-way analysis of 
variance (ANOVA) test using SPSS Statistics 22 (IBM, USA) was also performed on 











 Standard deviation = √





Σ =   the sum of 
𝑥   =   value 
?̅?   =   mean value 





4.1 Development of a basal chemically-defined medium (bCDM)  
 
A bCDM, which was devoid of carbon and nitrogen sources, was employed in the 
first part of the growth experiments to obtain reliable results in investigating the 
utilization of bovine glycosylated CMP by B. infantis ATCC 15697, B. bifidum ATCC 
29521 and B. longum ATCC 15707. The formula suggested by Hassinen et al. (1951) 
was used as a reference for the bCDM development in this project as their study 
contained the most relevant information.  
Literature has demonstrated a great heterogeneity of growth requirements among the 
Bifidobacterium spp. For example, B. adolescentis SI-30 synthesizes thiamin and 
nicotinic acid, but B. adolescentis E-194a does not synthesize them and indeed requires 
them for growth (Deguchi et al., 1985). Therefore, to determine the suitability of the 
formulas, preliminary experiments (an image is provided in Appendix 1) were carried 
out with potentially indispensable nutrients.  
 
4.1.1 Temporary nitrogen source of the bCDM 
 
A suitable nitrogen source had to be first identified to ensure that the bCDM can 
support the growth of the three strains. As D-glucose is the most common fermentable 
carbohydrate by Bifidobacterium spp., hence it was temporarily used as the base bCDM 
(Table 5) alongside with MgSO4, MnSO4 and L-cysteine which are known to support 
the growth of all bifidobacteria (Whitman et al., 2012). Other chemicals included in the 
base formula were NaCl (to balance the osmotic pressure between intracellular and 
extracellular environment), K2HPO4 (to act as a buffer), and bromocresol purple (to 
perceive bifidobacterial growth by detecting pH changes in the solution). The base 












K2HPO4.3H2O  2.0 
L-cysteine.HCl.H2O 0.5 
MgSO4 0.2 
MnSO4.H2O  0.1 
Bromocresol purple 0.03 
 
Sterile-filtered nitrogen sources were added into the base bCDM at single addition to 
distinguish the fermentable from non-fermentable ones, and the result is shown in Table 
6. Two ammonium salts were included among the eight nitrogen sources tested because 
certain strains, for instance B. adolescentis, can grow on ammonium salts as a sole 
nitrogen source (Matteuzzi et al., 1976). 
 
















Bacteriological peptone 2.0 + - + 
Tryptone 2.0 + - + 
Yeast extract 1.0 + + + 
Casamino acid 2.0 ± - + 
Sodium caseinate 1.0 - - ± 
Casein hydrolysate (acid) 1.0 ± - ± 
Ammonium sulfate 1.0 - - - 
Ammonium citrate tribasic 1.0 - - - 
+ : Growth detected as the solution turned yellow; 
± : Growth suspected as the solution turned slightly yellowish; 
-  : No growth detected as the solution remained purple.   
 
Both B. infantis ATCC 15697 and B. longum ATCC 15707 provided clearly positive 
results with the supplementation of bacteriological peptone or tryptone into the initial 
formula of bCDM. This leads to an inference that the substances in the current formula 
(Table 5) were sufficient to support the growth of these two strains. Bacteriological 
peptone was chosen as the nitrogen source in the subsequent step of the preliminary 
experiment since it is relatively more affordable than tryptone. Although all strains 
could grow very well upon the supplementation of yeast extract, but yeast extract is a 
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complex substance - it contains carbohydrates, B vitamins and trace minerals. 
Therefore, it was not included into consideration for further use. Nevertheless, it 
signified that B. bifidum requires additional B vitamins and/or trace minerals for growth.  
 
4.1.2 Other essential nutrients of the bCDM 
 
The subsequent experiment was carried out to identify the essential nutrients required 
by B. bifidum ATCC 29521 for growth. The composition of the base bCDM used at this 
stage is shown in Table 7. It was sterilized by autoclave and served as the control.  
 







Bacteriological peptone 2.0 
K2HPO4.3H2O  2.0 
L-cysteine.HCl.H2O 0.5 
MgSO4 0.2 
MnSO4.H2O  0.1 
Bromocresol purple 0.03 
 
Six B vitamins and four nucleobases were added into the base bCDM at single 
addition by sterile-filtration. However, each of them did not support the growth of B. 
bifidum. Thus, the vitamins and nucleobases were added in combination. The results are 























0.004 g/L thiamin 
 
- - + 
0.002 g/L nicotinic acid 
 
- - + 
A: 0.004 g/L thiamin + 0.002 g/L nicotinic acid 
 
- + + 
B: 0.002 g/L riboflavin + 0.002 g/L biotin  
+ 0.002 g/L cyanocobalamin + 0.002 g/L calcium 
pantothenate 
 
+ - + 
A + B 
 
+ + + 
A + 0.03 g/L uracil + 0.03 g/L xanthine  
+ 0.015 g/L adenine + 0.003 g/L guanine 
 
- + + 
+ : Growth detected as the solution turned yellow; 
-  : No growth detected as the solution remained purple.   
 
Notably, both thiamin and nicotinic acid were supportive for the growth of B. 
bifidum. The addition of riboflavin, calcium pantothenate, biotin, cyanocobalamin, 
uracil, xanthine, adenine, or guanine did not have major effect on its growth if both 
thiamin and nicotinic acid were present. In contrary, B. infantis could not grow in the 
presence of thiamin, nicotinic acid, or both; whereas B. longum can grow well with or 
without any additional nutrients.  
 
4.1.3 Finalized formula of the bCDM 
 
The base formula of the bCDM was then finalized by omitting the carbon and 
nitrogen sources (Table 9). As described in Section 3.4, sterilized base bCDM was used 
as the control, whereas the test group was supplemented with 10.0 g/L sterile-filtered 
CMP. Since the addition of thiamin and nicotinic acid seemed to negatively affect the 
growth of B. infantis ATCC 15697, the vitamins were added only for the tubes 










K2HPO4.3H2O  2.0 
L-cysteine.HCl.H2O 0.5 
MgSO4 0.2 
MnSO4.H2O  0.1 
Bromocresol purple 0.03 
Thiamin.HCl (for B. bifidum only) 0.004 
Nicotinic acid (for B. bifidum only) 0.002 
(Demineralized water) (1 L) 
 
 
4.2 Final cell counts in the growth experiments 
 
4.2.1 Slower microbial death in bCDM+CMP 
 
Significant decrement of cell counts was found in all inoculated media at the end of 
the incubation period instead of the expected growth (Table 10; Appendices 2-3). No 
growth was also revealed by the persistence of the purple color in the inoculated tubes.  
 




Cell counts (cfu/mL) 




















2.07 × 107 2.07 × 107 1.37 × 106   a 3.10 × 104   b 





4.2.2 Promoted microbial growth in MRS+CMP  
 
MRS was used in the second part of the growth experiments to allow normal growth 
of the strains. Bifidobacterial growth in MRS with or without CMP supplementation 
was compared (Table 11) to study about the growth-promoting effect of CMP. The fold-
change of each strain is defined by the ratio of final cell counts in CMP-supplemented 
broth to unsupplemented broth. 
 





Cell counts (cfu/mL) Fold-changes  
(i.e. ratio of final 





Start of incubation time  
(0 h) 
 





















7.56 × 106 7.56 × 106 9.27 × 108 8.15 × 108 1.1 
 
 
All strains reached higher cell counts in MRS+CMP compared to MRS. This result 
was expected because CMP represents additional nitrogen and carbon sources in the 
MRS medium. The fold-changes of B. infantis grew on MRS+CMP seemed to be 
slightly higher than B. bifidum and B. longum, though the difference in fold-changes 
was not significant (Appendix 4).  
Additional MRS agar plates of each inoculum were incubated aerobically to check 
for possible microbial contamination. All inocula had never been contaminated by other 
microbes, probably due to competitive exclusion. Interestingly, B. longum grew 
aerobically at 37oC but required twice as long incubation period as compared to the 
plates that were incubated in the anaerobic environment. This result was consistent with 
the observation of the culture tubes (Appendix 5) where B. longum was spread 
throughout the tube containing 10 mL MRS broth. Conversely, B. bifidum and B. 
infantis did not grow on the plates incubated aerobically and accumulated at the bottom 
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of the culture tubes where oxygen concentration was the lowest. Thus, B. longum ATCC 
15707 is an aerotolerant microbe, most probably due to the presence of enzymes that 
can repair oxidative damage like those present in B. longum NCC2705 (Schell et al., 
2002), while the other two strains are strict anaerobes.  
 
4.3 Final bound sialic acid contents in the growth experiments 
 
Bound sialic acid contents decreased in inoculated bCDM+CMP and MRS+CMP 
after incubation (Figure 6). The largest decrement was found in the media inoculated by 
B. infantis. Contrarily, the smallest decrement was obtained in the media inoculated by 
B. longum. This implies that the sialic acid residues from the glycosylated CMPs were 
cleaved and utilized the most by B. infantis, followed by B. bifidum and the least by B. 






Figure 6. Bound sialic acid contents in the media after designated hours of incubation. Note that the 
vertical axes scales are set at different intervals and do not begin at zero. Horizontal dotted 
lines indicate the levels of bound sialic acid in the negative controls. Error bars represent 
standard deviations of each mean value. No significant difference is found among the 















































The percentage differences of bound sialic acid contents between inoculated tubes 
and the respective controls can be found in Table 12. Generally, higher percentage of 
reduction in bound sialic acid contents is found in MRS+CMP than in bCDM+CMP, 
though no significant difference is present (Appendix 9).  
 
Table 12. Differences of sialic acid contents between bCDM+CMP and MRS+CMP with the respective 
control. 
 
Media Differences of 
bound sialic acid 













-0.095 ± 0.207 -0.041 ± 0.029 -0.017 ± 0.029 
% 
 
-7.6 -3.3 -1.4 
MRS+CMP g/L 
 
-0.059 ± 0.035 -0.047 ± 0.039 -0.045 ± 0.040 
% 
 
-12.6 -10.0 -9.5 
 
4.4 Reliability of acidic ninhydrin method  
 
A spike test was carried out to evaluate the accuracy of the acidic ninhydrin method 
in determining the bound sialic acid content in the media. Initially, a CMP assay of 2 
g/L was spiked by 50 nmol sialic acid before the precipitation by trichloroacetic acid 
(TCA). The results showed similar sialic acid contents between spiked and non-spiked 
samples. This leads to a conclusion that spiking at this stage was not appropriate as all 
free sialic acids will be lost alongside with the discard of the unwanted supernatant 
succeeding the TCA-precipitation step. Therefore, the CMP assay was spiked by 50 
nmol sialic acid after TCA-precipitation step but before heating. An acceptable mean 
recovery is between 90 to 110% (Liang et al., 2016). The result shown in Table 13 
implies that the method to measure sialic acid, as employed by Fukuda et al. (2004), 













(%) Spiked sample Original sample Standard added 
 
1 0.326 0.161 0.155 106.5 
2 0.315 0.161 0.155 99.4 
3 0.335 0.161 0.155 112.3 
 Mean recovery (%) 106.1 
 
The bound sialic acid content in the CMP powder was calculated (Table 14) and 
compared with the actual value to assess the effectiveness of the acid precipitation.   
 










Concentration of CMP (g/L) 
 
1.5 0.0 10.0 0.0 
Bound sialic acid contents 
(g/L) 
 
0.467 ± 0.042 0.324 ± 0.077 1.261 ± 0.060 0.010 ± 0.005 
Percentage (w/v) of bound 
sialic acid 
 in the CMP (%) 
 
9.5  12.5  
Percentage (w/v) of bound 
sialic acid originating from 
the CMP  
in the medium (%) 
 
0.01  0.13  
 
The calculation of 9.5% (w/v) of bound sialic acid in the CMP in MRS+CMP is close 
to the actual value of 9% (w/w) (Jers et al., 2014). This could imply that the acid 
precipitation was effective. However, the supplier stated that the sialic acid content may 
vary and a typical value is 4-6% (w/w). Therefore, relatively lower value obtained by 
the supplier might due to the different methods used for the sialic acid quantification.  
In short, acidic ninhydrin method represents a reliable and simple means to quantify 







5.1 Growth requirements of the strains  
 
A bCDM, which was devoid of carbon and nitrogen sources, was employed in the 
first part of the growth experiments to obtain reliable results in investigating the 
utilization of bovine glycosylated CMP by the strains.  
Notably, the result (Table 8) suggested that B. bifidum ATCC 29521 requires both 
thiamin and nicotinic acid to grow. The reason may be that this strain cannot synthesize 
the vitamins for its energy metabolism, unlike B. adolescentis SI-30 (Deguchi et al., 
1985). Conversely, the addition of thiamin, or nicotinic acid, or both into the base 
bCDM without the presence of other B vitamins seemed to exert an inhibition on the 
growth of B. infantis ATCC 15697. It is somewhat contradictory to the finding that this 
strain can synthesize thiamin and nicotinic acid, even with the addition of exogenous 
thiamin (Deguchi et al., 1985). One possible reason to explain the observed growth 
inhibition on B. infantis ATCC 15697 could be due to the elevated level of thiamin 
(0.004 g/L) added into the bCDM in this project, as compared to the highest 
concentration of 0.0002 g/L used by Deguchi et al. (1985). Although thiamin toxicity 
in bifidobacteria is not known to date, but excessive thiamin has shown to alter the 
enzymatic activities, and consequently inhibited the growth of Saccharomyces 
carlsbergensis ATCC 9080 in a vitamin B6-free medium (Nakamura et al., 1982).  
Literature has shown that Bifidobacterium spp. may grow on a simplified medium 
comprised of a fermentable carbohydrate, ammonium salt, buffers, minerals, cysteine 
as well as B vitamins (Hassinen et al., 1951). L-cysteine is required by most 
Bifidobacterium spp. for proper formation of proteins, in addition to lower the redox 
potential of the media (Ferrario et al., 2015). Thus, it is confirmed to be indispensable 
for Bifidobacterium spp. The minerals mentioned by Hassinen et al. (1951) refers to the 
combination of MgSO4.7H2O, FeSO4.7H2O, NaCl, and MnSO4.H2O, since the 
individual elimination of any of the minerals did not decrease the bifidobacterial growth. 
While magnesium is essential for the formation of cell wall in Gram-positive bacteria 
and for the activation of certain enzymes, manganese has the similar functions but to a 
lesser activity (Webb, 1951). This may be the reason why single-removal of the minerals 
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by Hassinen et al. (1951) did not affect the bifidobacterial growth. Hence, FeSO4.7H2O 
is not required for bifidobacterial growth as proven in this project, and possibly 
MnSO4.H2O as well.  
In short, the minimal medium allowing the growth of B. infantis ATCC 15697 and 
B. longum ATCC 15707 could be as simple as a fermentable carbohydrate, a protein 
source, buffers, MgSO4, and L-cysteine. Whereas B. bifidum ATCC 29521 requires 
thiamin and nicotinic acid in addition to the abovementioned nutrients/chemicals.  
 
5.2 Better microbial survival in bCDM+CMP 
 
In the first part of the growth experiments of this project, there was a drop in the cell 
counts in bCDM+CMP (Table 10). Microbial death, instead of cell proliferation, was 
most probably because the carbon source from glycosylated CMPs (0.13% w/v sialic 
acid in the bCDM+CMP; Table 14) was too scarce and quickly exhausted in the 
medium. Literature has shown that at least 0.4% (w/v) HMOs in a semi-synthetic MRS 
medium (without a carbohydrate source) is required for the growth of B. infantis ATCC 
15697 (Locascio et al., 2007).  
The slower death of all three strains in CMP-supplemented bCDM may indicate that 
it can act as the sole source of carbon and nitrogen in the medium for cellular 
metabolism. Thus, it is ascertained that the glycan chains attached to the glycosylated 
CMPs were utilized to some extent by all three strains via enzymatic degradation in a 
sequence-specific manner (Section 5.2.1).  
 
5.2.1 Enzymatic degradation of O-linked glycans 
 
The most abundant (56.0%) type of chain that attaches to a CMP is tetrasaccharides 
(Saito & Itoh, 1992). The removal of glycan chains from a glycoprotein occurs in a 
specific sequence (Figure 7). For the full utilization of the glycan chain, sialic acid 
residues must be removed prior to exposing the galacto-N-biose (GNB; it is also known 





Figure 7. Enzymatic degradation of a tetrasaccharides chain in O-linked glycosylation. The purple box 
depicts a GNB. Hydrolysis steps by respective enzymes are marked in red.  
 
5.2.2 Sialic acid cleavage 
 
Exo-α-sialidase is a glycoside hydrolase that cleaves α-glycosidic bonds of terminal 
sialic acid residues in oligosaccharides and glycoconjugates (Kiyohara et al., 2011).  
This enzyme is produced by B. infantis ATCC 15697 (Kiyohara et al., 2011; 
Locascio et al., 2007). With the aid of the binding proteins at the cell surface, the 
liberated sialic acid residues then transverses through ATP-binding cassette (ABC) 
transporters into the cell. Sialic acids are then further processed by the intracellular 
enzymes and ultimately generate energy in the cell (Appendix 10A) (Garrido et al, 2012; 
Sela et al., 2008).  
B. bifidum JCM1255 (same as ATCC 29521) demonstrated sialic acid-degrading 
activity in the studies carried out by Dank (2016), Ward et al. (2007), and Idota et al. 
(1994). Despite that, this strain does not produce exo-α-sialidase as B. bifidum JCM1254 
and B. bifidum JCM7004 do (Kiyohara et al., 2011). The sialic acid residues associated 
to a glycoprotein are released by a yet-to-be-characterized enzyme (putative sialidase) 
in B. bifidum ATCC 29521 but the generated free sialic acids are left unutilized (Milani 
et al., 2015; Ward et al., 2007).  
Similarly, exo-α-sialidase is not produced by B. longum JCM1217 (same as ATCC 
15707) (Kiyohara et al., 2011), but Dank (2016) and Idota et al. (1994) had found sialic 
1st step: exo-α-sialidase 
2nd step: endo-α-N-
acetylgalactosaminidase 
(O-glycosidase /  
O-glycanase) 
3rd step (intracellular):  





acid-degrading activity by this strain as well. Furthermore, Locascio et al. (2007) 
acknowledged a minimal and nonspecific sialidase activity in another closely related 
strain, which is B. longum DJO10A, despite it does not have exo-α-sialidase.  
 
5.2.3 Galacto-N-biose (GNB) cleavage 
 
Endo-α-N-acetylgalactosaminidase is a glycoside hydrolase that cleaves α-glycosidic 
bonds linking GalNAc-containing disaccharides with Ser or Thr residues, resulting in 
the release of the O-linked glycan chains from its conjugated peptide backbone 
(Koutsioulis et al., 2008).  
The enzyme is present in B. bifidum ATCC 29521 and B. longum ATCC 15707 as 
an extracellular enzyme (Fujita et al., 2005). After an intact GNB binds to the binding 
protein (in this case is known as “galacto-N-biose/lacto-N-biose I-binding protein” / 
GLBP) on the cell surface, endo-α-N-acetylgalactosaminidase removes it from its 
connected peptide backbone (Suzuki et al., 2008). The ABC transporter subsequently 
transverses the GNB into the cell. Finally, intracellular enzymes degrade it and utilize 
the monosaccharides for cellular metabolism (Appendix 10B) (Bruyn et al., 2013; 
Kitaoka et al., 2005).  
 Contrarily, endo-α-N-acetylgalactosaminidase is absent in B. infantis (Fujita et al., 
2005). The strain does not consume O-linked glycans but only N-linked glycans (Karav 
et al., 2016). Despite that, it imports all oligosaccharides into the cell via specific 
binding proteins and ABC transporters, then degrades the substrates intracellularly 
(Asakuma et al., 2011). The reason behind this is probably due to the genome adaptation 
of this strain to their habitat (human infant), and free oligosaccharides are primarily 
present in human milk (Ward et al., 2007). 
 
5.2.4 Utilization of the glycosylated CMP  
 
As a summary, the ability to utilize glycosylated CMP is strain-specific. B. infantis 
ATCC 15697 survived longer in bCDM+CMP by cleaving and utilizing the sialic acid 
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residues attached to the glycosylated CMPs, but it is theoretically not able to utilize the 
other glycans due to the lack of extracellular endo-α-N-acetylgalactosaminidase. 
Whereas, the presence of putative sialidases in B. bifidum ATCC 29521 and B. longum 
ATCC 15707, which has not been characterized yet, assisted in their survival in 
bCDM+CMP. Following the cleavage of terminal sialic acid residues from the glycan 
chains, both strains utilized the remaining intact GNB as a carbon source for their 
metabolism. It might also be that B. longum degraded the sialylated glycan chains 
without prior removal of the sialic acid residues, as demonstrated for sialyllacto-N-
tetraose (Odamaki et al., 2015).  
 
5.3 Growth-promoting effect of CMP on the tested strains 
 
MRS was used in the second part of the growth experiments in this project to allow 
normal growth of the strains. All strains reached higher cell counts in MRS+CMP than 
in MRS (Table 11). This result was also consistent with the study which demonstrated 
a shortened lag phase and a higher final cell count of B. bifidum CCDM94 attributed to 
the supplementation of CMP in the growth media (Cicvárek et al., 2010).  
This result was expected because CMP consists of a short polypeptide which is 
preferably used by Bifidobacterium spp. in comparison to large protein molecules 
(Robitaille, 2013). Additionally, the O-linked glycan chains attached to the CMPs are 
utilizable by the strains (Section 5.2). Although endo-α-N-acetylgalactosaminidase is 
theoretically absent in B. infantis in which results in the inability to degrade GNBs 
extracellularly, the abundance of carbon sources in MRS had probably masked that 
disadvantage over the other two strains.  
The fold-changes of B. infantis, B. bifidum and B. longum were 1.7, 1.5, and 1.1, 
respectively, as displayed in Table 11. B. longum had the lowest fold-change probably 
due to its inoculation of relatively higher initial cell counts than the other two strains. 
Low inocula were intended in this part of the growth experiments to intensify the 
growth-promoting effect of CMP (Brück et al., 2006). It has been shown that the 
bifidobacterial lag phase is inversely correlated with the initial cell count (Cicvárek et 
al., 2010). This means that a high inoculum reaches the maximal cell count considerably 
quicker than using a low inoculum in the same nutrient-rich medium. 
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5.4 Decrease of bound sialic acid contents in the inoculated media 
 
The largest decrement of bound sialic acid contents was found in the media 
inoculated by B. infantis (Figure 6). This result was expected as it produces exo-α-
sialidase which cleaves off terminal sialic acid residues from a glycan chain (Kiyohara 
et al., 2011). Whereas the loss of sialic acid in the media inoculated by B. bifidum and 
B. longum correlates with the better bifidobacterial survival in bCDM+CMP, therefore 
strengthens the possibility of sialidases in these two strains.  
Higher percentage of reduction in bound sialic acid contents is found in all inoculated 
MRS+CMP than in bCDM+CMP (Table 12). This is most probably due to the presence 
of other carbon sources in MRS which had supported the growth of the bifidobacteria, 
and induced the synthesis of glycoside hydrolases including sialidases. Consequently, 
more sialic acid residues were released from the glycan chains of the glycosylated CMPs 
in MRS+CMP than in bCDM+CMP. This was consistent with the report by Turroni et 
al. (2010) where B. bifidum PRL2010 produced ten times more endo-α-N-
acetylgalactosaminidase when growing on HMOs than growing on lactose as the sole 
carbon source.  
 
 




B. infantis ATCC 15697 can cleave and utilize sialic acids, but not other glycans, 
that are attached to the glycosylated CMPs; while both B. bifidum ATCC 29521 and B. 
longum ATCC 15707 can cleave terminal sialic acid residues, followed by the utilization 
of the glycans attached to the glycosylated CMPs other than sialic acids. This indicates 
that the hypothesis of “utilize all glycans attached to the CMP except sialic acids” by B. 
bifidum ATCC 29521 can be accepted; whereas the hypotheses of ‘a full utilization of 
glycosylated CMP’ by B. infantis ATCC 15697 and ‘a minimal utilization of 
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glycosylated CMP’ by B. longum ATCC 15707 should be rejected. It is therefore 
postulated that both B. bifidum ATCC 29521 and B. longum ATCC 15707 can produce 
sialidases to cleave sialic acid residues, which have not been characterized yet to date. 
This is supported by the slower death of all three strains in bCDM+CMP as compared 
to bCDM, and the reduction in bound sialic acid contents in inoculated media.  
Additionally, bovine CMP exerted a similar growth-promoting effect on all the 
strains because CMP consists of a short polypeptide which is preferably used by 
bifidobacteria. This conclusion was drawn based on the final cell counts of the three 
strains that were higher in MRS+CMP than in MRS. The growth-promoting effect of 
CMP on the strains did not differ significantly though, unlike what had been 
hypothesized “enhance the growth (with the effect intensity in descending order) of B. 
infantis, B. bifidum, and B. longum”. Moreover, the presence of other carbon sources in 
MRS might induce the synthesis of glycoside hydrolases in the strains, particularly 
sialidases, therefore leading to a higher percentage of reduction in bound sialic acid 
contents in MRS+CMP than in bCDM+CMP.  
From an industrial point of view (for example, functional ingredients manufacturers), 
it is feasible to add bovine CMP, which is largely found in the rennet whey during 




Further research on the putative sialidases in B. bifidum ATCC 29521 and B. longum 
ATCC 15707 is warranted. This can be done by identifying the potential genes, cloning 
the genes, and characterizing the recombinant proteins (an example of method by 
Kiyohara et al., 2012). Additionally, the use of microplate reader is highly 
recommended for the research on bacteria. It not only consumes less materials, but also 
enables the monitoring of bacterial growth in real time, thus more accurate growth curve 
can be obtained (Brewster, 2003).  
The determination of free sialic acid is also recommended so that it is possible to 
distinguish the ability between the cleavage and the utilization of sialic acid by the 
strains. Alternatively, it may be useful to culture the strains in 13C-labelled free sialic 
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acid (an example of method by Young et al., 2015) to learn the metabolism of free sialic 
acids by the strains.  
Apart from that, development of a minimal medium could be done as inferred in the 
last paragraph of Section 5.1. A variation to the parameters used in the growth 
experiments of this project could also be done in future works. Examples are extending 
the incubation period to several days to obtain the complete growth curves of the strains, 
supplementing the media with different concentrations of CMP to determine its effect 
on the bifidobacterial growth, as well as co-inoculating B. infantis and B. bifidum into 
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Appendix 2: MRS agar plates of bCDM+CMP and bCDM 
 
























Appendix 5: Overnight culture tubes 
 



























Appendix 7: Bound sialic acid contents in bCDM and bCDM+CMP  
and the ANOVA test result 
 
Specimens Bound sialic acid contents (g/L) Differences of bound sialic 
acid contents with the 
control 
 
Tube 1 Tube 2 Mean ± 
Standard 
deviation 




Control 0.013 0.007 0.010 ± 0.005  
Small differences may due 
to random errors 
B. infantis 0.006 0.008 0.007 ± 0.001 
B. bifidum 0.014 0.008 0.011 ± 0.004 




Control 1.219 1.304 1.261 ± 0.060  
B. infantis 0.977 1.355 1.166 ± 0.267 -0.095 (-7.6%) 
B. bifidum 1.157 1.283 1.220 ± 0.090 -0.041 (-3.3%) 






Appendix 8: Bound sialic acid contents in MRS and MRS+CMP  
and the ANOVA test result 
 
Specimens Bound sialic acid contents (g/L) Differences of bound sialic 
acid contents with the 
control 
Tube 1 Tube 2 Mean ± 
Standard 
deviation 




Control 0.378 0.270 0.324 ± 0.077  
B. infantis 0.266 0.280 0.273 ± 0.010 -0.051 (-15.7%) 
B. bifidum 0.316 0.261 0.288 ± 0.039 -0.036 (-11.0%) 




Control 0.497 0.437 0.467 ± 0.042  
B. infantis 0.414 0.403 0.409 ± 0.008 -0.059 (-12.5%) 
B. bifidum 0.423 0.418 0.421 ± 0.004 -0.046 (-9.9%) 






Appendix 9: ANOVA test result of the difference of sialic acid contents between 











Appendix 10: Intracellular metabolic pathways of sialic acid and GNB 
 










Appendix 11: Product specification of CMP  
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Appendix 12: Product specification of PFZ  






Appendix 13: Product specification of MRS  
(Oxoid, UK) 
 
 
 
 
 
